Jonas Kildegaard, Stephen T Buckley, Rasmus H Nielsen, Gro K Povlsen, Torben Seested, Ulla Ribel, Helle B Olsen, Svend Ludvigsen, Claus B Jeppesen, Hanne H F Refsgaard, Kristian M Bendtsen, Niels R Kristensen, Susanne Hostrup, Jeppe Sturis
PURPOSE: Fast-acting insulin aspart (faster aspart) is a novel formulation of insulin aspart containing two additional excipients: niacinamide, to increase early absorption, and L-arginine, to optimize stability. The aim of this study was to evaluate the impact of niacinamide on insulin aspart absorption and to investigate the mechanism of action underlying the accelerated absorption. METHODS: The impact of niacinamide was assessed in pharmacokinetic analyses in pigs and humans, small angle X-ray scattering experiments, trans-endothelial transport assays, vascular tension measurements, and subcutaneous blood flow imaging...
February 11, 2019: Pharmaceutical Research